Axion Biosystems
Discover the biology you can't see
Company details
Year Aquired
2021
Location
Atlanta GA, United States
Revenue (2020)
USD 11.4
Sector
BEA (Bioelectronic Assay)
Employees
60+
Investment Themes
Changing Demographics
Contact
If you want to know more about Axion Biosystems please contact Tommi Unkuri at: tommi.unkuri@summaequity.com
Website
Axion at a glance
Axion Biosystems is a US based life science tools business specialized in developing, producing, and marketing BEA (Bioelectronic Assay) instruments for customers in biopharma and academia.
Axion’s products enable scientists to understand many aspects of cell function in real-time, giving them insight into, e.g., electric activity, synchrony, oscillation, growth, shape change, and potency of a cell. Understanding of cell function is highly relevant for many pharmaceutical segments, e.g., development of cell and gene therapies.
Recent developments
In 2020, Axion Biosystems launched several new applications on their instruments. Neural, Cardiac, Impedance, and Impedance GxP Software Modules for Maestro Pro and Edge were introduced, and the company also launched its new premium Impedance instrument Maestro ZHT in November 2020. The Maestro ZHT is an advanced high throughput impedance-based cell analysis system for label-free oncology, virology, cellular kinetics assays. This allows clients to screen drug and biological candidates in 384- and 96-well plate formats.
Impact Dimensions
The challenges we face
Healthcare systems face great challenges in terms of the quality of patient outcomes produced in the system, and waste related to ineffective treatment regimes. Healthcare systems need better tools to target disease in more effective ways and create better outcomes. The research community that is driving the development of such tools has a great need to improve its understanding of biology and understanding cell function is central to some of the most important questions related to this work. Tools for analyzing cell function is important for many pharmaceutical segments, including the development of cell and gene therapies. BEA technology provides academic and biopharma organizations the ability to deepen their understanding of cell function, enabling faster, more accurate and more cost-efficient drug discovery and development, as well as improved quality control in drug production processes.
What is the outcome?
The products offered by Axion Biosystems allows academia and biopharma to understand aspects of cell function in real-time, giving them insight into, e.g., the activity, synchrony, oscillation, growth, shape change and potency of a cell. This enables these researchers to improve the time, cost and quality of drug development processes.
Who are the stakeholders?
The products are used by academia and biopharma customers. Eventually, the ultimate beneficiary of the research conducted by these stakeholders are the patients, that get access to better treatment.
How big is the effect, and does it last?
Understanding cell function is central to some of the most critical pharmaceutical segments, including the development of cell and gene therapies. Such therapies can be life saving for patients, and improved healthcare solutions like these will change outcomes for relevant patient groups for the foreseeable future.
If Axion Biosystems didn’t exist…
Without Axion’s products, scientists would lack access to a powerful tool, needed to understand many aspects of cell function in real-time. This would make research on relevant new healthcare tools more difficult.
Impact risk: what can go wrong
Product quality is fundamentally important, so if Axion cannot deliver the required product quality, its customers would likely stop using its products, being left with less efficient tools to conduct their research.
Year Aquired
2021
Revenue (2020)
USD 11.4
Employees
60+
Investment Themes
Changing Demographics
Sector
BEA (Bioelectronic Assay)
Location
Atlanta GA, United States
Contact
If you want to know more about Axion Biosystems please contact Tommi Unkuri at: tommi.unkuri@summaequity.com
